Two biotech IPOs make debut

Investor's Business Daily
September 2014
Investors Business Daily;9/19/2014, pA02
Cystic fibrosis therapy developer


Related Articles

  • The Big Lift. Sweeney, Paul // Investment Dealers' Digest;11/06/2000, Vol. 66 Issue 43, p26 

    Reports on trends in the financing of biotechnology companies in the United States. Growth in the genomics sector that contributed to investor interest in the industry; Outcomes of biotechnology initial public offerings; Trading of biotechnology stocks.

  • FINANCINGS ROUNDUP.  // BioWorld Today;4/9/2007, Vol. 18 Issue 68, p8 

    The article presents news briefs on financial issues in the biotechnology industry. A registration statement for a proposed public offering in common stock has been filed by A.P. Pharma Inc. A direct offering of 14.1 million shares of common stock has been completed by Discovery Laboratories...

  • Immunomedics Raises $24M For Anticancer Antibodies. Morrison, Trista // BioWorld Today;5/3/2007, Vol. 18 Issue 86, p4 

    The article offers news briefs related to companies involved in the world biotechnology industry. Immunomedica Inc. is offering 4.8 million shares at 44.95 each to raise $24 million. Javelin Pharmaceuticals Inc. is planning to sell shares to fund its specialty pharmaceutical pain drugs. Orexigen...

  • Financing Roundup.  // BioWorld Today;11/5/2013, Vol. 24 Issue 213, p14 

    This section offers news briefs on financing initiatives by biophamaceutical companies as of November 2013 including a private offering by Ignyta Inc., a public offering by Tetraphase Pharmaceuticals Inc. and an initial public offering (IPO) by Xencor Inc.

  • Financings Roundup.  // BioWorld Today;2/14/2014, Vol. 25 Issue 31, p7 

    The article announces that the underwriters of the public offering of Puma Biotechnology Inc. exercised their option in purchasing additional shares at 122.50 dollars each.

  • Ablynx Growing Post-IPO, Adds $68M to Advance Nanobodies. Sheridan, Cormac // BioWorld International;3/17/2010, Vol. 15 Issue 11, p1 

    The article reports on a follow-on public offering completed by Ablynx NV. About 6.7 million shares were offered at 7.50 euro per share. The 50 million euros offering takes the company's total equity investment to more than 206 million euros. The offering attracted several local and...

  • Amarin Raises $91.2M in Public Offering for AMR101 Sales Prep. Morrison, Trista // BioWorld Today;1/7/2011, Vol. 22 Issue 5, p1 

    The article reports on the 91.2 million dollars raised by Dublin, Ireland-based biotechnology company Amarin Corp. in a public offering of American Depositary Shares, with Phase III trials of its triglyceride-lowering drug AMR101 (ethyl icosapentate) nearly complete. It says that the current...

  • IPO Window Opening? Tesaro Prices Within Expected Range. Winter, Peter // BioWorld Today;6/29/2012, Vol. 23 Issue 126, p1 

    The article reports that biopharmaceutical company Tesaro Inc. has completed an initial public offering (IPO), selling 6 million shares at 13.50 U.S. dollars per share. Tesaro granted the underwriters a 30-day option to buy up to 900,000 shares of common stocks. It is noted that biotechnology...

  • Private cash in hand, Orchid seeks IPO underwriter. Lacey, Stephen // Investment Dealers' Digest;01/17/2000, Vol. 66 Issue 3, p5 

    Reports that biotechnology firm Orchid Biocomputer Inc. is choosing an investment bank to underwrite an upcoming initial public offering. Capital raised through a self-managed private placement scheme; Reason for the success of the private placement; Outline of the company's fund raising...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics